Background There are no disease-modifying treatments for dementia. There is also no consensus on disease modifying outcomes. We aimed to produce the first evidence-based consensus on core outcome measures for trials of disease modification in mild-to-moderate dementia. ... View more
1. Lewis F. Estimation of future cases of dementia from those born in 2015. Office of Health Economics Consulting Reports. 2015.
2. PhRMA. Researching Alzheimer's medicines: Setbacks and stepping stones. 2012.
Department oHaPMsO. G8 dementia summit declaration. 2013.
4. Lewis F, Karlsberg Schaffer S, Sussex J. The Trajectory of Dementia in the UK-Making a Difference. Office of Health Economics Consulting Reports. 2014.
5. Zoda TE. New Standards in Alzheimer's Disease Trial Design. Therpeutics, Journal for Clinical Studies. 2014; 6(2):44±5.
6. Rubinstein E, Duggan C, Van Landingham B, Thompson D, Warburton W. A call to action: the global response to dementia through policy innovation. 2015.
7. Long R. Challenges to finding treatments for dementia. 2015.
8. Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016; 12(1):60±4. https://doi. org/10.1016/j.jalz.2015.12.003 PMID: 26710325
9. Harrison JK, Noel-Storr AH, Demeyere N, Reynish EL, Quinn TJ. Outcomes measures in a decade of dementia and mild cognitive impairment trials. Alzheimer's Research & Therapy. 2016; 8(1):48.
Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, et al. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment 2017; 21(26). https://doi.org/10.3310/hta21260 PMID: 28625273